# Advanced Centre for Treatment, Research and Education in Cancer

Source: https://onco.cc/institutions/actrec/  
OnCo record `actrec` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The research and development campus of Tata Memorial Centre, where India's first indigenous CAR-T therapy was developed and low-cost trials are designed.

## Summary

ACTREC opened in Kharghar, Navi Mumbai, in 2002 as the research wing of Tata Memorial Centre, combining basic science laboratories, a clinical research centre and a hospital that has since expanded into a large cancer hospital with bone marrow transplant, proton and paediatric services. Its scientists, with IIT Bombay and ImmunoACT, developed talicabtagene autoleucel (NexCAR19), India's first approved CD19 CAR-T therapy, and ACTREC hosts the Tata Memorial biobank, genomics and proteomics facilities and the Clinical Research Secretariat that ran the low-dose nivolumab and metronomic chemotherapy trials. The campus also houses the Homi Bhabha National Institute's cancer biology PhD programme and an early-phase trial unit.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: ACTREC; Tata Memorial Centre ACTREC
- City: Navi Mumbai, IN
- Type: research-institute
- Website: https://actrec.gov.in

## Sources

- ACTREC: https://actrec.gov.in
- Tata Memorial Centre: https://tmc.gov.in
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Global oncology and access in low- and middle-income countries](https://onco.cc/technologies/global-oncology-access/), [Point-of-care and decentralised cell manufacturing](https://onco.cc/technologies/point-of-care-cell-manufacturing/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Buccal mucosa and gingivobuccal cancer (oral cancer in India)](https://onco.cc/cancers/buccal-mucosa-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Talicabtagene autoleucel](https://onco.cc/drugs/talicabtagene-autoleucel/)
- institutions: [Indian Institute of Technology Bombay](https://onco.cc/institutions/iit-bombay/), [National Cancer Grid of India](https://onco.cc/institutions/national-cancer-grid/), [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- people: [Kumar Prabhash](https://onco.cc/people/prabhash-kumar/), [Pankaj Chaturvedi](https://onco.cc/people/chaturvedi-pankaj/), [Rajendra Badwe](https://onco.cc/people/badwe-rajendra/), [Sudeep Gupta](https://onco.cc/people/gupta-sudeep/), [Vijay Patil](https://onco.cc/people/patil-vijay/)
- companies: [ImmunoACT](https://onco.cc/companies/immunoact/)
- trials: [Talicabtagene autoleucel (NexCAR19) phase 1/2](https://onco.cc/trials/talicel-phase-1-2/)

---
JSON: https://onco.cc/api/v1/entities/actrec.json